EUVIMEDEUVIMED entdecken
Crossref

Plectalibertellenone A suppresses colorectal cancer cell motility and glucose metabolism by targeting TGF‐β/Smad and Wnt pathways

Chathurika D B Gamage iD, Jeong-Hyeon Kim, Rui Zhou, So-Yeon Park, Sultan Pulat iD, Mücahit Varlı, Sang-Jip Nam, Hangun Kim iD

BioFactors · 2025

DOI: 10.1002/biof.2120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioFactors, 2025. Verfasst von Chathurika D B Gamage und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Sunchon National University, Sunchon, Jeonnam, Korea. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Cell Movement, Glucose, Wnt Signaling Pathway. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is the second most common cause of cancer‐related death and represents a serious worldwide health problem. CRC metastasis decreases the survival rate of cancer patients, underscoring the need to identify novel anticancer agents and therapeutic targets. Here, we introduce Plectalibertellenone A ( B ) as a promising agent for the inhibition of CRC cell motility and glucose metabolism and explore its mechanism of action in CRC cells. Plectalibertellenone A suppressed TGF‐β gene expression and the activation of the TGF‐β/Smad signaling pathway, leading to reverse epithelial to mesenchymal transition (EMT) by modulating the expressions of EMT markers and transcriptional factors such as E‐cadherin, N‐cadherin, vimentin, Slug, Snail, Twist, and ZEB1/2. Furthermore, disruption of Wnt signaling inhibited CRC motility and glucose metabolism including glycolysis and oxidative phosphorylation, primarily affecting glycolytic enzymes, GLUT1, HK2, PKM2, LDHA, and HIF‐1α under hypoxic condition. Therefore, Plectalibertellenone A is a potential drug candidate that can be developed into a promising anticancer treatment to prevent CRC metastasis and inhibit glucose metabolism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCell MovementGlucoseWnt Signaling PathwayTransforming Growth Factor betaEpithelial-Mesenchymal TransitionHumansCell Line, TumorSmad ProteinsGene Expression Regulation, NeoplasticCell Proliferation

Stichwörter der Autor:innen

CRCEMTPlectalibertellenone A (B)aerobic glycolysismotilityoxidative phosphorylation

Substanzen

GlucoseTransforming Growth Factor betaSmad Proteins

Autor:innen und Institutionen

  • College of Pharmacy, Sunchon National University, Sunchon, Jeonnam, Korea.
  • Department of Chemistry and Nanoscience, Ewha Woman University, Seoul, Korea.

ORCID-Profile: Chathurika D B Gamage, Sultan Pulat, Hangun Kim

Zitieren

APA

Gamage, C. D. B., Kim, J. H., Zhou, R., Park, S. Y., Pulat, S., Varlı, M., Nam, S. J., & Kim, H. (2025). Plectalibertellenone A suppresses colorectal cancer cell motility and glucose metabolism by targeting TGF‐β/Smad and Wnt pathways. BioFactors. https://doi.org/10.1002/biof.2120

Vancouver

Gamage CDB, Kim JH, Zhou R, Park SY, Pulat S, Varlı M, et al. Plectalibertellenone A suppresses colorectal cancer cell motility and glucose metabolism by targeting TGF‐β/Smad and Wnt pathways. BioFactors. 2025. doi:10.1002/biof.2120

BibTeX
@article{Gamage2025,
  author = {Gamage, Chathurika D B and Kim, Jeong-Hyeon and Zhou, Rui and Park, So-Yeon and Pulat, Sultan and Varlı, Mücahit and Nam, Sang-Jip and Kim, Hangun},
  title = {Plectalibertellenone A suppresses colorectal cancer cell motility and glucose metabolism by targeting TGF‐β/Smad and Wnt pathways},
  journal = {BioFactors},
  year = {2025},
  doi = {10.1002/biof.2120}
}
Kostenlos starten →